Carlos M DeCastro
Overview
Explore the profile of Carlos M DeCastro including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
756
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Morris T, DeCastro C, Diehl L, Gockerman J, Lagoo A, Li Z, et al.
Leuk Res
. 2012 Oct;
37(1):28-31.
PMID: 23046833
Purpose: The decision to re-induce patients with acute myeloid leukemia (AML) based on results of the day 14 bone marrow (BM) biopsy is variable and lacks evidence based data. The...
2.
Lanasa M, Davis P, Datto M, Li Z, Gockerman J, Moore J, et al.
Leuk Lymphoma
. 2011 Aug;
53(2):218-24.
PMID: 21827374
Patients with chronic lymphocytic leukemia (CLL) with deletion or mutation of TP53 have exceedingly poor clinical outcomes. Cenersen, an oligonucleotide targeting TP53, has been shown to abrogate the activity of...
3.
Friedman D, Weinberg J, Barry W, Goodman B, Volkheimer A, Bond K, et al.
Clin Cancer Res
. 2009 Oct;
15(22):6947-55.
PMID: 19861443
Purpose: Chronic lymphocytic leukemia (CLL) is a B-cell malignancy characterized by a variable clinical course. Several parameters have prognostic capabilities but are associated with altered response to therapy in only...
4.
Rizzieri D, OBrien J, Broadwater G, DeCastro C, Dev P, Diehl L, et al.
Cancer
. 2009 May;
115(13):2922-9.
PMID: 19452542
Background: Response and survival in 96 patients with secondary acute myeloid leukemia (sAML) who received aggressive induction chemotherapy was reviewed. Methods: The median follow-up of survivors was 2.3 years. A...
5.
Greenberg P, Attar E, Battiwalla M, Bennett J, Bloomfield C, DeCastro C, et al.
J Natl Compr Canc Netw
. 2008 Oct;
6(9):902-26.
PMID: 18926100
No abstract available.
6.
Rao A, Younis I, Sand G, Spasojevic I, Adams D, DeCastro C, et al.
Leuk Lymphoma
. 2008 Sep;
49(8):1523-9.
PMID: 18766965
Our aim was to estimate the duration of maximum tolerated dose (MTD) duration for gemcitabine given as a continuous infusion in combination with fludarabine and mitoxantrone and to evaluate potential...
7.
Weinberg J, Volkheimer A, Chen Y, Beasley B, Jiang N, Lanasa M, et al.
Am J Hematol
. 2007 Jul;
82(12):1063-70.
PMID: 17654680
Several parameters may predict disease severity and overall survival in chronic lymphocytic leukemia (CLL). The purpose of our study of 190 CLL patients was to compare immunoglobulin heavy chain variable...
8.
Talbot J, Ibom V, Rizzieri D, Barrier R, Niedzwieki D, DeCastro C, et al.
Clin Lymphoma
. 2004 Sep;
5(2):116-22.
PMID: 15453927
A retrospective review was performed on the toxicity and response to one cycle of dose-intense cyclophosphamide/etoposide, followed by consolidation in patients with refractory or previously untreated, high-risk non-Hodgkin's lymphoma (NHL)....
9.
Nishimura J, Kanakura Y, Ware R, Shichishima T, Nakakuma H, Ninomiya H, et al.
Medicine (Baltimore)
. 2004 May;
83(3):193-207.
PMID: 15118546
: To determine and directly compare the clinical course of white and Asian patients with paroxysmal nocturnal hemoglobinuria (PNH), data were collected for epidemiologic analysis on 176 patients from Duke...
10.
Ibom V, Prosnitz R, Gong J, Moore J, DeCastro C, Prosnitz L, et al.
Clin Lymphoma
. 2003 Oct;
4(2):115-8.
PMID: 14556684
Rituximab in combination with chlorambucil or radiation therapy may be an effective and less-toxic therapeutic alternative for patients with lymphocyte predominance Hodgkin's disease (LPHD). We treated 6 patients with LPHD...